Consensus Cytokinetics, Incorporated

Stocks

CYTK

US23282W6057

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 18:44:45 08/06/2026 BST			5-day change	1st Jan Change
68.84 ^USD	-3.69%		-6.96%	+7.88%

06-02	Cytokinetics Insider Sold Shares Worth $1,111,200, According to a Recent SEC Filing	MT
06-01	Cytokinetics announces launch of Myqorzo (aficamten) in Germany for symptomatic obstructive hypertrophic cardiomyopathy	RE

Evolution of the Average Target: Cytokinetics, Incorporated

Evolution of the Target Price: Cytokinetics, Incorporated

Changes in Analyst Recommendations: Cytokinetics, Incorporated

e14.YliHo7B5fpdWtvom--eQGl2qjYp9T9eYtvTyj9oU8KA.Iwj25oZLS_wQga5-lLXyfxn4_cgxF5vg44zG2Z1LnOEuFvP22zcH_BCHiQ~9b5fff402f27b19d8995dba32cf0c0af

Analysts' recommendations: Cytokinetics, Incorporated

05-06	Cytokinetics' Rapid Growth of Myqorzo not Fully Priced in by Investors, RBC Says	MT
05-06	B. Riley Adjusts Price Target on Cytokinetics to $146 From $108, Maintains Buy Rating	MT
05-06	RBC Adds Speculative Risk to Outperform Rating on Cytokinetics, Lifts Price Target to $119 From $101	MT
04-24	Edgewise Therapeutics Faces Near-Term Upside From Cytokinetics' Upcoming Readout, RBC Says	MT
03-19	Mizuho Raises Price Target on Cytokinetics to $100 From $84, Keeps Outperform Rating	MT
02-20	RBC Raises Price Target on Cytokinetics to $101 From $95, Keeps Outperform, Speculative Risk	MT
02-03	Truist Raises Price Target on Cytokinetics to $92 From $84, Keeps Buy Rating	MT
01-21	B. Riley Raises Price Target on Cytokinetics to $108 From $90, Keeps Buy Rating	MT
12-22	RBC Raises Price Target on Cytokinetics to $95 From $87, Keeps Outperform, Speculative Risk	MT
11-11	Cytokinetics' 2026 Aficamten Launch Could Gain From Differentiated Strategy, RBC Says	MT
11-11	RBC Raises Price Target on Cytokinetics to $87 From $82, Keeps Outperform, Speculative Risk	MT
11-10	B. Riley Adjusts Price Target on Cytokinetics to $90 From $80, Maintains Buy Rating	MT
22/09/25	B. Riley Raises Price Target on Cytokinetics to $80 From $74, Keeps Buy Rating	MT
03/09/25	Analyst recommendations: Accenture, Chipotle, Kraft, Lucid Group, Thor Industries…
07/08/25	Biopharma firm Cytokinetics Q2 revenue jumps	RE
09/06/25	Analyst recommendations: Broadcom, Lululemon, McDonald's, Tesla, Etsy…
29/05/25	Mizuho Cuts Price Target on Cytokinetics to $84 From $103, Keeps Outperform Rating	MT
08/05/25	B. Riley Adjusts Cytokinetics Price Target to $74 From $88, Maintains Buy Rating	MT
07/05/25	RBC Trims Price Target on Cytokinetics to $80 From $82, Keeps Outperform, Speculative Risk	MT
02/05/25	UBS Adjusts Price Target on Cytokinetics to $41 From $47, Maintains Neutral Rating	MT
17/03/25	UBS Lowers Price Target on Cytokinetics to $47 From $61, Maintains Neutral Rating	MT
28/02/25	Oppenheimer Adjusts Price Target on Cytokinetics to $96 From $98, Maintains Outperform Rating	MT
13/02/25	Morgan Stanley Upgrades Cytokinetics to Overweight From Equalweight, Adjusts Price Target to $67 From $70	MT
13/02/25	Morgan Stanley Upgrades Cytokinetics to Overweight From Equalweight, Trims Price Target to $67 From $70	MT
13/02/25	Analyst recommendations: Diageo, Glencore, Prudential, Coca-Cola, Spotify…

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CYTOKINETICS, INCORPORATED					+46.47%
	ARGENX SE					+10.53%
	WUXI APPTEC CO., LTD.					+51.16%
	BIONTECH SE					+40.53%
	INSMED INCORPORATED					+111.76%
	WUXI BIOLOGICS (CAYMAN) INC.					+43.27%
	GENMAB A/S					+46.08%
	EXELIXIS, INC.					-5.79%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+39.21%
	SUMMIT THERAPEUTICS INC.					+92.65%
	Average					+47.59%
	Weighted average by Cap.					+42.45%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

71.48USD

Average target price

104.70USD

Spread / Average Target

+46.47%

High Price Target

146.00USD

Spread / Highest target

+104.25%

Low Price Target

69.00USD

Spread / Lowest Target

-3.47%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

B. Riley
RBC Capital Markets
Mizuho Securities
Truist Securities
UBS
Oppenheimer
Morgan Stanley
Citigroup
Stifel Nicolaus
JMP Securities
Raymond James
Needham & Co.
HC Wainwright
Cantor Fitzgerald
Goldman Sachs
SVB Securities LLC
JPMorgan Chase
BofA Securities
Piper Sandler
Jefferies & Co.
Barclays
Wolfe Research